Black Hawk Shareholders Approve Vesicor Merger; 2.09M Shares Redeemed for $25.2M
BKHA sits 31% above its 52-week low of $9.5 on elevated volume (1.8× avg).
Summary
Black Hawk shareholders approved the Vesicor merger and all related proposals on October 13, 2026, but 2.09M shares were redeemed for $25.2M, cutting the trust account roughly in half and intensifying cash concerns. Estimated trust remaining is $420,377 with about 2.06M Class A shares outstanding, subject to final reconciliation.
Updated with a Wiseek News report · What changed
Updates
· Wiseek News — Estimated trust remaining is $420,377 with about 2.06M Class A shares outstanding, subject to final reconciliation.
- Ticker symbol will be VESI post-close.
Key Events · M&A and Partnerships · BKHA
-
New · · Wiseek News
Ticker Symbol VESI Post-Close
Ticker symbol will be VESI post-close.
-
Updated · · Wiseek News
Massive Redemptions Drain Trust
2,089,162 shares were redeemed for $25,153,510.48 at approximately $12.04 per share, representing about 50% of the 4,153,577 shares outstanding. Estimated trust remaining is $420,377 with about 2.06M Class A shares outstanding, subject to final reconciliation.
-
All Eight Merger Proposals Approved
Shareholders approved the Vesicor business combination, domestication to Delaware, new organizational documents, director elections, Nasdaq listing, incentive plan, NTA removal, and adjournment authority.
-
NTA Requirement Removed
The $5,000,001 net tangible assets requirement was eliminated, a governance concession reflecting the company's weak balance sheet.
-
Five Directors Elected
Luo Feng, Warren Hosseinion, Frederick Woodruff Field, Oded Levy, and Qi Ouyang were elected to the post-merger board.
Analysis · BKHA · Life Sciences
Black Hawk's shareholders approved all eight proposals needed to complete the Vesicor Therapeutics business combination, clearing the final governance hurdle. However, 2,089,162 shares — roughly half of the 4.15M outstanding — were redeemed for $25.15M at $12.04 per share, draining the trust account and leaving the combined company with significantly less cash than anticipated. The NTA proposal also removes the $5M net tangible assets requirement, a concession that reflects the company's precarious financial position. With only $12,052 in cash reported in the last 10-Q and going concern doubts persisting, the merger's completion now hinges on the Meteora financing package closing as planned. Estimated trust remaining is $420,377 with about 2.06M Class A shares outstanding, subject to final reconciliation.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.5% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKHA was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.8M. The 52-week trading range was $9.50 to $23.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.